- Type 2 diabetes treatment market value in Asia-Pacific (APAC) will rise from an estimated $6.5 billion in 2013 to $10.5 billion by 2020
- 'The increasing diabetic population in India and China is the major reason behind the diabetes treatment market growth in the APAC region,' says analyst
NEW YORK (GBI Research), 6 January 2015
The type 2 diabetes treatment market in Asia-Pacific (APAC) will rise in value from an estimated $6.5 billion in 2013 to $10.5 billion by 2020, representing a modest Compound Annual Growth Rate (CAGR) of 7.1%, according to business intelligence provider GBI Research.
The company's latest report* states that of the four major APAC countries (China, India, Japan and Australia), China will see the fastest expansion, with a CAGR of 11.1% over the forecast period. This will be driven by an increase in the prevalent population due to urbanization, and by expected drug launches.
Arti Singh, Analyst for GBI Research, says: "The increasing diabetic population in India and China is the major reason behind the diabetes treatment market growth in the APAC region as a whole.
"While Metformin is expected to retain its dominant position in the treatment algorithm for type 2 diabetes, the anticipated launch of promising pipeline molecules, including several drugs with novel mechanisms of action, may also contribute to market expansion."
The analyst notes that there is uncertainty in the future type 2 diabetes treatment market, as sulfonylureas are currently the favored combination drugs with metformin, and a number of promising GLP-1 agonists, SGLT inhibitors and DPP-4 inhibitors are in the pipeline.
Singh continues: "While sulfonylureas typically have a very low annual cost of therapy, the pipeline drugs are expected to have a very high cost, meaning that even a small swing in their market penetration will have a significant impact on growth.
"However, if these late-stage pipeline drugs fail to show consistently strong efficacy profiles across Phase III trials, or are found to have a slight chance of causing a serious adverse event, such as cancer, their commercial potential will be severely reduced."
The analyst concludes that the widespread use of sulfonylureas and metformin, and the high level of competition among pipeline drugs, which could reduce the rate at which novel drugs can enter the market, will be the main barriers to market expansion over the forecast period.
*Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth
-ENDS-
-NOTES TO EDITOR-
This report provides analysis of type 2 diabetes treatment use patterns, market characterization, pipeline and key licensing and co-development deals in the Asia-Pacific markets of China, India, Japan, and Australia.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.
-ABOUT GBI RESEARCH-
GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.
For more information, please contact our Press Office on +44 (0)1204 543 537 or at [email protected].